Slide
Centre Interdisciplinaire
de Recherche et d’Innovation
en Cybersécurité et Société
de Recherche et d’Innovation
en Cybersécurité et Société
1.
Scholten, W.; Seldenrijk, A.; Hoogendoorn, A.; Bosman, R.; Muntingh, A.; Karyotaki, E.; Andersson, G.; Berger, T.; Carlbring, P.; Furmark, T.; Bouchard, S.; Goldin, P.; Kampmann, I.; Morina, N.; Kocovski, N.; Leibing, E.; Leichsenring, F.; Stolz, T.; Balkom, A. Van; Batelaan, N.
In: JAMA Psychiatry, vol. 80, no. 8, pp. 822–831, 2023, ISSN: 2168622X (ISSN), (Publisher: American Medical Association).
Abstract | Links | BibTeX | Tags: adult, antidepressant agent, Anxiety disorder, article, avoidant personality disorder, clinical outcome, cognitive behavioral therapy, comorbidity, cycloserine, Depression, disease severity, female, hospital admission, human, Humans, Liebowitz Social Anxiety Scale, male, meta analysis, paroxetine, phobia, Preferred Reporting Items for Systematic Reviews and Meta-Analyses, procedures, psychotropic agent, randomized controlled trial (topic), Randomized Controlled Trials as Topic, semi structured interview, Social, social anxiety, social phobia, Structured Clinical Interview for DSM Disorders, symptom, systematic review, treatment response, Waiting Lists
@article{scholten_baseline_2023,
title = {Baseline Severity as a Moderator of the Waiting List-Controlled Association of Cognitive Behavioral Therapy with Symptom Change in Social Anxiety Disorder: A Systematic Review and Individual Patient Data Meta-analysis},
author = {W. Scholten and A. Seldenrijk and A. Hoogendoorn and R. Bosman and A. Muntingh and E. Karyotaki and G. Andersson and T. Berger and P. Carlbring and T. Furmark and S. Bouchard and P. Goldin and I. Kampmann and N. Morina and N. Kocovski and E. Leibing and F. Leichsenring and T. Stolz and A. Van Balkom and N. Batelaan},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85166386036&doi=10.1001%2fjamapsychiatry.2023.1291&partnerID=40&md5=c279c8b0ff2d3b4558c6f8803cdda0af},
doi = {10.1001/jamapsychiatry.2023.1291},
issn = {2168622X (ISSN)},
year = {2023},
date = {2023-01-01},
journal = {JAMA Psychiatry},
volume = {80},
number = {8},
pages = {822–831},
abstract = {Importance: Social anxiety disorder (SAD) can be adequately treated with cognitive behavioral therapy (CBT). However, there is a large gap in knowledge on factors associated with prognosis, and it is unclear whether symptom severity predicts response to CBT for SAD. Objective: To examine baseline SAD symptom severity as a moderator of the association between CBT and symptom change in patients with SAD. Data Sources: For this systematic review and individual patient data meta-analysis (IPDMA), PubMed, PsycInfo, Embase, and the Cochrane Library were searched from January 1, 1990, to January 13, 2023. Primary search topics were social anxiety disorder, cognitive behavior therapy, and randomized controlled trial. Study Selection: Inclusion criteria were randomized clinical trials comparing CBT with being on a waiting list and using the Liebowitz Social Anxiety Scale (LSAS) in adults with a primary clinical diagnosis of SAD. Data Extraction and Synthesis: Authors of included studies were approached to provide individual-level data. Data were extracted by pairs of authors following the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and risk of bias was assessed using the Cochrane tool. An IPDMA was conducted using a 2-stage approach for the association of CBT with change in LSAS scores from baseline to posttreatment and for the interaction effect of baseline LSAS score by condition using random-effects models. Main Outcomes and Measures: The main outcome was the baseline to posttreatment change in symptom severity measured by the LSAS. Results: A total of 12 studies including 1246 patients with SAD (mean [SD] age, 35.3 [10.9] years; 738 [59.2%] female) were included in the meta-analysis. A waiting list-controlled association between CBT and pretreatment to posttreatment LSAS change was found (b = -20.3; 95% CI, -24.9 to -15.6; P <.001; Cohen d = -0.95; 95% CI, -1.16 to -0.73). Baseline LSAS scores moderated the differences between CBT and waiting list with respect to pretreatment to posttreatment symptom reductions (b = -0.22; 95% CI, -0.39 to -0.06; P =.009), indicating that individuals with severe symptoms had larger waiting list-controlled symptom reductions after CBT (Cohen d = -1.13 [95% CI, -1.39 to -0.88] for patients with very severe SAD; Cohen d = -0.54 [95% CI, -0.80 to -0.29] for patients with mild SAD). Conclusions and Relevance: In this systematic review and IPDMA, higher baseline SAD symptom severity was associated with greater (absolute but not relative) symptom reductions after CBT in patients with SAD. The findings contribute to personalized care by suggesting that clinicians can confidently offer CBT to individuals with severe SAD symptoms.. © 2023 American Medical Association. All rights reserved.},
note = {Publisher: American Medical Association},
keywords = {adult, antidepressant agent, Anxiety disorder, article, avoidant personality disorder, clinical outcome, cognitive behavioral therapy, comorbidity, cycloserine, Depression, disease severity, female, hospital admission, human, Humans, Liebowitz Social Anxiety Scale, male, meta analysis, paroxetine, phobia, Preferred Reporting Items for Systematic Reviews and Meta-Analyses, procedures, psychotropic agent, randomized controlled trial (topic), Randomized Controlled Trials as Topic, semi structured interview, Social, social anxiety, social phobia, Structured Clinical Interview for DSM Disorders, symptom, systematic review, treatment response, Waiting Lists},
pubstate = {published},
tppubtype = {article}
}
Importance: Social anxiety disorder (SAD) can be adequately treated with cognitive behavioral therapy (CBT). However, there is a large gap in knowledge on factors associated with prognosis, and it is unclear whether symptom severity predicts response to CBT for SAD. Objective: To examine baseline SAD symptom severity as a moderator of the association between CBT and symptom change in patients with SAD. Data Sources: For this systematic review and individual patient data meta-analysis (IPDMA), PubMed, PsycInfo, Embase, and the Cochrane Library were searched from January 1, 1990, to January 13, 2023. Primary search topics were social anxiety disorder, cognitive behavior therapy, and randomized controlled trial. Study Selection: Inclusion criteria were randomized clinical trials comparing CBT with being on a waiting list and using the Liebowitz Social Anxiety Scale (LSAS) in adults with a primary clinical diagnosis of SAD. Data Extraction and Synthesis: Authors of included studies were approached to provide individual-level data. Data were extracted by pairs of authors following the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and risk of bias was assessed using the Cochrane tool. An IPDMA was conducted using a 2-stage approach for the association of CBT with change in LSAS scores from baseline to posttreatment and for the interaction effect of baseline LSAS score by condition using random-effects models. Main Outcomes and Measures: The main outcome was the baseline to posttreatment change in symptom severity measured by the LSAS. Results: A total of 12 studies including 1246 patients with SAD (mean [SD] age, 35.3 [10.9] years; 738 [59.2%] female) were included in the meta-analysis. A waiting list-controlled association between CBT and pretreatment to posttreatment LSAS change was found (b = -20.3; 95% CI, -24.9 to -15.6; P <.001; Cohen d = -0.95; 95% CI, -1.16 to -0.73). Baseline LSAS scores moderated the differences between CBT and waiting list with respect to pretreatment to posttreatment symptom reductions (b = -0.22; 95% CI, -0.39 to -0.06; P =.009), indicating that individuals with severe symptoms had larger waiting list-controlled symptom reductions after CBT (Cohen d = -1.13 [95% CI, -1.39 to -0.88] for patients with very severe SAD; Cohen d = -0.54 [95% CI, -0.80 to -0.29] for patients with mild SAD). Conclusions and Relevance: In this systematic review and IPDMA, higher baseline SAD symptom severity was associated with greater (absolute but not relative) symptom reductions after CBT in patients with SAD. The findings contribute to personalized care by suggesting that clinicians can confidently offer CBT to individuals with severe SAD symptoms.. © 2023 American Medical Association. All rights reserved.
2.
Ikic, V.; Bélanger, C.; Bouchard, S.; Gosselin, P.; Langlois, F.; Labrecque, J.; Dugas, M. J.; Marchand, A.
Reduction in costs after treating comorbid panic disorder with agoraphobia and generalized anxiety disorder Journal Article
In: Journal of Mental Health Policy and Economics, vol. 20, no. 1, pp. 11–20, 2017, ISSN: 10914358, (Publisher: ICMPE).
Abstract | Links | BibTeX | Tags: adult, agoraphobia, Anxiety disorder, Anxiety Disorders, article, cognitive behavioral therapy, cognitive therapy, comorbidity, controlled study, dysthymia, economics, female, follow up, generalized anxiety disorder, health care cost, Health Care Costs, human, Humans, major clinical study, major depression, male, Mental health, obsessive compulsive disorder, panic, Panic Disorder, phobia, posttraumatic stress disorder, procedures, Quebec, social phobia, statistics and numerical data
@article{ikic_reduction_2017,
title = {Reduction in costs after treating comorbid panic disorder with agoraphobia and generalized anxiety disorder},
author = {V. Ikic and C. Bélanger and S. Bouchard and P. Gosselin and F. Langlois and J. Labrecque and M. J. Dugas and A. Marchand},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018690998&partnerID=40&md5=0d0600e6dd4e2a381f733ac063d639dc},
issn = {10914358},
year = {2017},
date = {2017-01-01},
journal = {Journal of Mental Health Policy and Economics},
volume = {20},
number = {1},
pages = {11–20},
abstract = {Background: Panic disorder with agoraphobia (PDA) and generalized anxiety disorder (GAD) are impairing and costly disorders that are often misdiagnosed and left untreated despite multiple consultations. These disorders frequently co-occur, but little is known about the costs associated with their comorbidity and the impact of cognitive-behavioral therapy (CBT) on cost reduction. Aims of the Study: The first objective of this study was to assess the mental health-related costs associated with the specific concomitance of PDA and GAD. The second aim was to determine whether there is a reduction in direct and indirect mental healthrelated costs following conventional CBT for the primary disorder only (PDA or GAD) or combined CBT adapted to the comorbidity (PDA and GAD). Methods: A total of 123 participants with a double diagnosis of PDA and GAD participated in this study. Direct and indirect mental health-related costs were assessed and calculated from a societal perspective at the pre-Test, the post-Test, and the three-month, sixmonth and one-year follow-ups. Results: At the pre-Test, PDA-GAD comorbidity was found to generate a mean total cost of CAD2,000.48 (SD = 2,069.62) per participant over a three-month period. The indirect costs were much higher than the direct costs. Both treatment modalities led to significant and similar decreases in all cost categories from the pretest to the post-Test. This reduction was maintained until the oneyear follow-up. Discussion: Methodological choices may have underestimated cost evaluations. Nonetheless, this study supports the cost offset effects of both conventional CBT for primary PDA or GAD and combined CBT for PDA-GAD comorbidity. Implications for Healthcare Provision and Use: Treatment of comorbid and costly disorders with evidence-based treatments such as CBT may lead to considerable economic benefits for society. Implications for Health Policies: Considering the limited resources of healthcare systems, it is important to make choices that will lead to better accessibility of quality services. The application of CBT for PDA, GAD or both disorders and training mental health professionals in this therapeutic approach should be encouraged. Additionally, it would be favorable for insurance plans to reimburse employees for expenses associated with psychological treatment for anxiety disorders. Implications for Further Research: In addition to symptom reduction, it would be of great pertinence to explore which factors can contribute to reducing direct and indirect mental health-related costs. © 2017 ICMPE.},
note = {Publisher: ICMPE},
keywords = {adult, agoraphobia, Anxiety disorder, Anxiety Disorders, article, cognitive behavioral therapy, cognitive therapy, comorbidity, controlled study, dysthymia, economics, female, follow up, generalized anxiety disorder, health care cost, Health Care Costs, human, Humans, major clinical study, major depression, male, Mental health, obsessive compulsive disorder, panic, Panic Disorder, phobia, posttraumatic stress disorder, procedures, Quebec, social phobia, statistics and numerical data},
pubstate = {published},
tppubtype = {article}
}
Background: Panic disorder with agoraphobia (PDA) and generalized anxiety disorder (GAD) are impairing and costly disorders that are often misdiagnosed and left untreated despite multiple consultations. These disorders frequently co-occur, but little is known about the costs associated with their comorbidity and the impact of cognitive-behavioral therapy (CBT) on cost reduction. Aims of the Study: The first objective of this study was to assess the mental health-related costs associated with the specific concomitance of PDA and GAD. The second aim was to determine whether there is a reduction in direct and indirect mental healthrelated costs following conventional CBT for the primary disorder only (PDA or GAD) or combined CBT adapted to the comorbidity (PDA and GAD). Methods: A total of 123 participants with a double diagnosis of PDA and GAD participated in this study. Direct and indirect mental health-related costs were assessed and calculated from a societal perspective at the pre-Test, the post-Test, and the three-month, sixmonth and one-year follow-ups. Results: At the pre-Test, PDA-GAD comorbidity was found to generate a mean total cost of CAD2,000.48 (SD = 2,069.62) per participant over a three-month period. The indirect costs were much higher than the direct costs. Both treatment modalities led to significant and similar decreases in all cost categories from the pretest to the post-Test. This reduction was maintained until the oneyear follow-up. Discussion: Methodological choices may have underestimated cost evaluations. Nonetheless, this study supports the cost offset effects of both conventional CBT for primary PDA or GAD and combined CBT for PDA-GAD comorbidity. Implications for Healthcare Provision and Use: Treatment of comorbid and costly disorders with evidence-based treatments such as CBT may lead to considerable economic benefits for society. Implications for Health Policies: Considering the limited resources of healthcare systems, it is important to make choices that will lead to better accessibility of quality services. The application of CBT for PDA, GAD or both disorders and training mental health professionals in this therapeutic approach should be encouraged. Additionally, it would be favorable for insurance plans to reimburse employees for expenses associated with psychological treatment for anxiety disorders. Implications for Further Research: In addition to symptom reduction, it would be of great pertinence to explore which factors can contribute to reducing direct and indirect mental health-related costs. © 2017 ICMPE.
3.
Cousineau, H.; Marchand, A.; Bouchard, S.; Bélanger, C.; Gosselin, P.; Langlois, F.; Labrecque, J.; Dugas, M. J.; Belleville, G.
Insomnia symptoms following treatment for comorbid panic disorder with agoraphobia and generalized anxiety disorder Journal Article
In: Journal of Nervous and Mental Disease, vol. 204, no. 4, pp. 267–273, 2016, ISSN: 00223018, (Publisher: Lippincott Williams and Wilkins).
Abstract | Links | BibTeX | Tags: adult, agoraphobia, antidepressant agent, Anxiety Disorders, anxiolytic agent, article, clinical trial, cognitive therapy, cohort analysis, Cohort Studies, Combined Modality Therapy, comorbidity, comparative study, controlled study, Depression, disease severity, female, generalized anxiety disorder, human, Humans, hypnotic agent, insomnia, major clinical study, male, Middle Aged, multicenter study, multimodality cancer therapy, nocturnal panic attack, panic, Panic Disorder, panic disorder with agoraphobia, patient worry, procedures, psychoeducation, psychology, psychotropic agent, Psychotropic Drugs, quasi experimental study, Quebec, randomized controlled trial, Sleep Initiation and Maintenance Disorders, statistical significance, treatment outcome, wakefulness, Young Adult
@article{cousineau_insomnia_2016,
title = {Insomnia symptoms following treatment for comorbid panic disorder with agoraphobia and generalized anxiety disorder},
author = {H. Cousineau and A. Marchand and S. Bouchard and C. Bélanger and P. Gosselin and F. Langlois and J. Labrecque and M. J. Dugas and G. Belleville},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84962128029&doi=10.1097%2fNMD.0000000000000466&partnerID=40&md5=2ca2dd82c29553bd7377ba64dd5522cc},
doi = {10.1097/NMD.0000000000000466},
issn = {00223018},
year = {2016},
date = {2016-01-01},
journal = {Journal of Nervous and Mental Disease},
volume = {204},
number = {4},
pages = {267–273},
abstract = {Patients with panic disorder with agoraphobia (PDA) or generalized anxiety disorder (GAD) frequently also suffer from insomnia. However, the impact of cognitive-behavioral therapy (CBT) for anxiety disorders on insomnia has been understudied. Furthermore, comorbidity between anxiety disorders is common. Our main objective was to assess the impact of CBT for PDA or GAD on insomnia. In a quasi-experimental design, 86 participants with PDA and GAD received conventional CBT for their primary disorder or combined CBT for both disorders. Overall, CBTs had a significant impact on reducing insomnia symptoms (η2 = 0.58). However, among people with insomnia at pretest (67%), 33% still had an insomnia diagnosis, and the majority (63%) had clinically significant residual insomnia following treatment. In conclusion, the CBTs had a positive effect on the reduction of insomnia, but a significant proportion of participants still had insomnia problems following treatment. Clinicians should address insomnia during CBT for PDA and GAD. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.},
note = {Publisher: Lippincott Williams and Wilkins},
keywords = {adult, agoraphobia, antidepressant agent, Anxiety Disorders, anxiolytic agent, article, clinical trial, cognitive therapy, cohort analysis, Cohort Studies, Combined Modality Therapy, comorbidity, comparative study, controlled study, Depression, disease severity, female, generalized anxiety disorder, human, Humans, hypnotic agent, insomnia, major clinical study, male, Middle Aged, multicenter study, multimodality cancer therapy, nocturnal panic attack, panic, Panic Disorder, panic disorder with agoraphobia, patient worry, procedures, psychoeducation, psychology, psychotropic agent, Psychotropic Drugs, quasi experimental study, Quebec, randomized controlled trial, Sleep Initiation and Maintenance Disorders, statistical significance, treatment outcome, wakefulness, Young Adult},
pubstate = {published},
tppubtype = {article}
}
Patients with panic disorder with agoraphobia (PDA) or generalized anxiety disorder (GAD) frequently also suffer from insomnia. However, the impact of cognitive-behavioral therapy (CBT) for anxiety disorders on insomnia has been understudied. Furthermore, comorbidity between anxiety disorders is common. Our main objective was to assess the impact of CBT for PDA or GAD on insomnia. In a quasi-experimental design, 86 participants with PDA and GAD received conventional CBT for their primary disorder or combined CBT for both disorders. Overall, CBTs had a significant impact on reducing insomnia symptoms (η2 = 0.58). However, among people with insomnia at pretest (67%), 33% still had an insomnia diagnosis, and the majority (63%) had clinically significant residual insomnia following treatment. In conclusion, the CBTs had a positive effect on the reduction of insomnia, but a significant proportion of participants still had insomnia problems following treatment. Clinicians should address insomnia during CBT for PDA and GAD. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
4.
Katzman, M. A.; Bleau, P.; Blier, P.; Chokka, P.; Kjernisted, K.; Ameringen, M. Van; Antony, M. M.; Bouchard, S.; Brunet, A.; Flament, M.; Rabheru, K.; Grigoriadis, S.; Richter, P. M. A.; Mendlowitz, S.; O'Connor, K.; Robichaud, M.; Walker, J. R.; Asmundson, G.; Klassen, L. R.; Lam, R. W.; McIntyre, R. S.; Szpindel, I.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Journal Article
In: BMC Psychiatry, vol. 14, no. SUPPL.1, 2014, ISSN: 1471244X (ISSN), (Publisher: BioMed Central Ltd.).
Abstract | Links | BibTeX | Tags: agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine
@article{katzman_canadian_2014,
title = {Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders},
author = {M. A. Katzman and P. Bleau and P. Blier and P. Chokka and K. Kjernisted and M. Van Ameringen and M. M. Antony and S. Bouchard and A. Brunet and M. Flament and K. Rabheru and S. Grigoriadis and P. M. A. Richter and S. Mendlowitz and K. O'Connor and M. Robichaud and J. R. Walker and G. Asmundson and L. R. Klassen and R. W. Lam and R. S. McIntyre and I. Szpindel},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903778611&doi=10.1186%2f1471-244X-14-S1-S1&partnerID=40&md5=4787fc6f97c204c1428770a5e4a57a00},
doi = {10.1186/1471-244X-14-S1-S1},
issn = {1471244X (ISSN)},
year = {2014},
date = {2014-01-01},
journal = {BMC Psychiatry},
volume = {14},
number = {SUPPL.1},
abstract = {Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.},
note = {Publisher: BioMed Central Ltd.},
keywords = {agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine},
pubstate = {published},
tppubtype = {article}
}
Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.
5.
Yuen, E. K.; Herbert, J. D.; Forman, E. M.; Goetter, E. M.; Juarascio, A. S.; Rabin, S.; Goodwin, C.; Bouchard, S.
Acceptance based behavior therapy for social anxiety disorder through videoconferencing Journal Article
In: Journal of Anxiety Disorders, vol. 27, no. 4, pp. 389–397, 2013, ISSN: 18737897 (ISSN).
Abstract | Links | BibTeX | Tags: acceptance based behavior therapy, adult, agoraphobia, alcoholism, article, avoidance behavior, Beck Depression Inventory, behavior therapy, Behavioral Assessment Test, Brief Version of the Fear of Negative Evaluation Scale, clinical article, clinical trial, comorbidity, disability, effect size, Feasibility Studies, feasibility study, female, follow up, Follow-Up Studies, generalized anxiety disorder, human, Humans, interview, Liebowitz Social Anxiety Scale, major depression, male, named inventories, panic, patient attitude, Patient Satisfaction, phobia, Phobic Disorders, Pilot Projects, pilot study, procedures, Psychiatric Status Rating Scales, psychologic test, Psychological, psychological rating scale, psychotherapist attitude, quality of life, questionnaires and rating scales, Skype, social anxiety, social phobia, Social Phobia and Anxiety Inventory, Structured Clinical Interview for DSM Disorders, telehealth, Telemedicine, Telemental health, Telepsychology, treatment outcome, videoconferencing
@article{yuen_acceptance_2013,
title = {Acceptance based behavior therapy for social anxiety disorder through videoconferencing},
author = {E. K. Yuen and J. D. Herbert and E. M. Forman and E. M. Goetter and A. S. Juarascio and S. Rabin and C. Goodwin and S. Bouchard},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879799248&doi=10.1016%2fj.janxdis.2013.03.002&partnerID=40&md5=a280b967176db691df32f37d15cb52a1},
doi = {10.1016/j.janxdis.2013.03.002},
issn = {18737897 (ISSN)},
year = {2013},
date = {2013-01-01},
journal = {Journal of Anxiety Disorders},
volume = {27},
number = {4},
pages = {389–397},
abstract = {Most individuals with social anxiety disorder (SAD) do not receive any type of treatment. Reasons include logistical barriers (e.g., geographic location, travel time), fear of stigmatization, and fear of the social interactions associated with seeking treatment. Videoconferencing technology holds great promise in the widespread delivery of evidence-based treatments to those who would otherwise not receive treatment. This pilot study assessed the feasibility, acceptability, and initial efficacy of an acceptance-based behavioral intervention using Skype videoconferencing to treat adults with generalized SAD. Twenty-four participants received 12 sessions of weekly therapy and were assessed at pre-treatment, mid-treatment, post-treatment, and 3-month follow-up. Participants and therapists rated the intervention as acceptable and feasible. Analyses revealed significant pre-treatment to follow-up improvements in social anxiety, depression, disability, quality of life, and experiential avoidance, with effect sizes comparable to or larger than previously published results of studies delivering in-person CBT for SAD. Implications and future directions are discussed. © 2013 Elsevier Ltd.},
keywords = {acceptance based behavior therapy, adult, agoraphobia, alcoholism, article, avoidance behavior, Beck Depression Inventory, behavior therapy, Behavioral Assessment Test, Brief Version of the Fear of Negative Evaluation Scale, clinical article, clinical trial, comorbidity, disability, effect size, Feasibility Studies, feasibility study, female, follow up, Follow-Up Studies, generalized anxiety disorder, human, Humans, interview, Liebowitz Social Anxiety Scale, major depression, male, named inventories, panic, patient attitude, Patient Satisfaction, phobia, Phobic Disorders, Pilot Projects, pilot study, procedures, Psychiatric Status Rating Scales, psychologic test, Psychological, psychological rating scale, psychotherapist attitude, quality of life, questionnaires and rating scales, Skype, social anxiety, social phobia, Social Phobia and Anxiety Inventory, Structured Clinical Interview for DSM Disorders, telehealth, Telemedicine, Telemental health, Telepsychology, treatment outcome, videoconferencing},
pubstate = {published},
tppubtype = {article}
}
Most individuals with social anxiety disorder (SAD) do not receive any type of treatment. Reasons include logistical barriers (e.g., geographic location, travel time), fear of stigmatization, and fear of the social interactions associated with seeking treatment. Videoconferencing technology holds great promise in the widespread delivery of evidence-based treatments to those who would otherwise not receive treatment. This pilot study assessed the feasibility, acceptability, and initial efficacy of an acceptance-based behavioral intervention using Skype videoconferencing to treat adults with generalized SAD. Twenty-four participants received 12 sessions of weekly therapy and were assessed at pre-treatment, mid-treatment, post-treatment, and 3-month follow-up. Participants and therapists rated the intervention as acceptable and feasible. Analyses revealed significant pre-treatment to follow-up improvements in social anxiety, depression, disability, quality of life, and experiential avoidance, with effect sizes comparable to or larger than previously published results of studies delivering in-person CBT for SAD. Implications and future directions are discussed. © 2013 Elsevier Ltd.
6.
Savard, J.; Laberge, B.; Gauthier, J. G.; Founder, J. -P.; Bouchard, S.; Baril, J. -G.; Bergeron, M. G.
In: Cognitive Therapy and Research, vol. 22, no. 1, pp. 21–46, 1998, ISSN: 01475916 (ISSN), (Publisher: Springer New York LLC).
Abstract | Links | BibTeX | Tags: adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome
@article{savard_combination_1998,
title = {Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation},
author = {J. Savard and B. Laberge and J. G. Gauthier and J. -P. Founder and S. Bouchard and J. -G. Baril and M. G. Bergeron},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031957952&doi=10.1023%2fA%3a1018759802082&partnerID=40&md5=bf7c480d95e52b00202cfcb1f34af74f},
doi = {10.1023/A:1018759802082},
issn = {01475916 (ISSN)},
year = {1998},
date = {1998-01-01},
journal = {Cognitive Therapy and Research},
volume = {22},
number = {1},
pages = {21–46},
abstract = {The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline experimental design with follow-up and direct replications. Results of time-series intervention analyses suggest that the combination of fluoxetine and cognitive therapy can provide an effective treatment for major depression in HIV illness that may be more effective than fluoxetine alone. However, relapse rates and follow-up results raise some concerns about the long-term efficacy of the combined treatment as administered in this study. Cooccurence of a personality disorder is suggested as an explanatory hypothesis.},
note = {Publisher: Springer New York LLC},
keywords = {adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome},
pubstate = {published},
tppubtype = {article}
}
The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline experimental design with follow-up and direct replications. Results of time-series intervention analyses suggest that the combination of fluoxetine and cognitive therapy can provide an effective treatment for major depression in HIV illness that may be more effective than fluoxetine alone. However, relapse rates and follow-up results raise some concerns about the long-term efficacy of the combined treatment as administered in this study. Cooccurence of a personality disorder is suggested as an explanatory hypothesis.